Rabbit Polyclonal Cannabinoid Receptor I antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 4 publications. Immunogen corresponding to Synthetic Peptide within Human CNR1 aa 250-400.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 79.99% PBS, 20% Glycerol (glycerin, glycerine)
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Mouse | Tested | Expected |
Rat | Tested | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000.00000 - 1/10000.00000 | Notes - |
Species Rat | Dilution info 1/1000.00000 - 1/10000.00000 | Notes - |
Species Human | Dilution info 1/1000.00000 - 1/10000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Suggested antigen retrieval using heat mediated 10mM Citrate buffer (pH6.0) or Tris-EDTA buffer (pH8.0). |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC) (PubMed:15620723, PubMed:27768894, PubMed:27851727). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner (PubMed:17895407). In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a pro-inflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells (PubMed:23955712). Isoform 1. Binds both 2-arachidonoylglycerol (2-AG) and anandamide. Isoform 2. Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 2 in assays measuring GTP binding to membranes. Isoform 3. Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 3 in assays measuring GTP binding to membranes.
CNR, CNR1, Cannabinoid receptor 1, CB-R, CB1, CANN6
Rabbit Polyclonal Cannabinoid Receptor I antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 4 publications. Immunogen corresponding to Synthetic Peptide within Human CNR1 aa 250-400.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 79.99% PBS, 20% Glycerol (glycerin, glycerine)
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
7.5% SDS PAGE
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody (ab137410) at 1/5000 dilution
All lanes: Mouse brain whole cell lysate at 50 µg
Predicted band size: 53 kDa
7.5% SDS PAGE
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody (ab137410) at 1/5000 dilution
All lanes: Rat brain whole cell lysate at 50 µg
Predicted band size: 53 kDa
10 % SDS-PAGE
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody (ab137410) at 1/1000 dilution
Lane 1: HEK 293T whole cell lysate at 10 µg
Lane 2: HEK 293T whole cell lysate transfected with Cannabinoid Receptor I at 10 µg
Predicted band size: 18 kDa, 261 kDa, 35 kDa, 39 kDa, 46 kDa, 53 kDa
10 % SDS-PAGE
All lanes: Western blot - Anti-Cannabinoid Receptor I antibody (ab137410) at 1/1000 dilution
All lanes: U87-MG whole cell lysate at 30 µg
Predicted band size: 53 kDa
Immunohistochemical analysis of paraffin-embedded OVCA, labelling Cannabinoid Receptor I using ab137410 at 1/100 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com